Invasive mould disease is a growing threat for immunocompromised patients. The optimum time to use mould-active antifungal agents is much debated. Current approaches to antifungal prophylaxis, early treatment (empirical and pre-emptive therapy) and treatment of documented mould infections in onco-haematology patients are discussed
Patients at risk of, or diagnosed with, an invasive fungal infection benefit from an early antifunga...
Diagnosis, treatment, and management of invasive mould infections (IMI) are challenged by several ri...
Invasive fungal diseases are important causes of morbidity and mortality in immunocompromised patien...
Invasive mould disease is a growing threat for immunocompromised patients. The optimum time to use m...
Invasive mould disease is a growing threat for immunocompromised patients. The optimum time to use m...
Different therapeutic strategies for invasive fungal diseases have been explored, each with particul...
Timely diagnosis and treatment of invasive mould disease is challenging in severely immunocompromise...
Invasive mould infections (IMIs), such as invasive aspergillosis or mucormycosis, are a major cause ...
Diagnosis, treatment, and management of invasive mould infections (IMI) are challenged by several ri...
Treatment duration for invasive mold disease (IMD) in patients with hematological malignancy is not ...
Invasive fungal infections present with a rising incidence and high morbidity and mortality rates. A...
The management of pulmonary mold infections in at-risk patients is hampered by the difficulty in dia...
Patients receiving intensive anti-leukemic treatment or recipients of allogeneic hematopoietic stem ...
Antifungal treatment duration and changes for invasive mould infections (IMI) have been poorly descr...
Invasive mould diseases (IMDs) are often encountered in haematologic patients who undergo chemothera...
Patients at risk of, or diagnosed with, an invasive fungal infection benefit from an early antifunga...
Diagnosis, treatment, and management of invasive mould infections (IMI) are challenged by several ri...
Invasive fungal diseases are important causes of morbidity and mortality in immunocompromised patien...
Invasive mould disease is a growing threat for immunocompromised patients. The optimum time to use m...
Invasive mould disease is a growing threat for immunocompromised patients. The optimum time to use m...
Different therapeutic strategies for invasive fungal diseases have been explored, each with particul...
Timely diagnosis and treatment of invasive mould disease is challenging in severely immunocompromise...
Invasive mould infections (IMIs), such as invasive aspergillosis or mucormycosis, are a major cause ...
Diagnosis, treatment, and management of invasive mould infections (IMI) are challenged by several ri...
Treatment duration for invasive mold disease (IMD) in patients with hematological malignancy is not ...
Invasive fungal infections present with a rising incidence and high morbidity and mortality rates. A...
The management of pulmonary mold infections in at-risk patients is hampered by the difficulty in dia...
Patients receiving intensive anti-leukemic treatment or recipients of allogeneic hematopoietic stem ...
Antifungal treatment duration and changes for invasive mould infections (IMI) have been poorly descr...
Invasive mould diseases (IMDs) are often encountered in haematologic patients who undergo chemothera...
Patients at risk of, or diagnosed with, an invasive fungal infection benefit from an early antifunga...
Diagnosis, treatment, and management of invasive mould infections (IMI) are challenged by several ri...
Invasive fungal diseases are important causes of morbidity and mortality in immunocompromised patien...